NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Gut Bacteria Molecule Boosting Immunotherapy Response
TL;DR
This discovery could give companies like Calidi Biotherapeutics a competitive edge in developing more effective lung cancer immunotherapies.
Scientists identified a gut bacteria molecule called Bac429 that enhances immunotherapy response in lung cancer, now being developed for human trials.
This breakthrough offers hope for better cancer treatment outcomes, potentially improving survival and quality of life for patients.
Gut bacteria produce a molecule that supercharges the immune system to fight lung cancer more effectively in mice.
Found this article helpful?
Share it with your network and spread the knowledge!
Scientists have identified a compound called Bac429 produced by gut bacteria that sharply improves how tumors respond to immunotherapy, offering a potential breakthrough for patients who currently see little benefit from these treatments.
The discovery enhances immunotherapy response, specifically improving lung cancer treatment outcomes in mice according to the research.
The molecule is called Bac429, and it is now being developed into a drug suitable for human trials.
This discovery is significant because it offers potential benefits for patients who currently see little improvement from existing immunotherapy treatments, potentially expanding effective treatment options.
Research has been conducted on mice, showing that Bac429 enhanced lung cancer treatment outcomes, and the findings have been published in a scientific journal.
This content was published by TinyGems, a specialized communications platform focused on innovative small-cap and mid-cap companies with bright futures and potential, which is part of the IBN (Investor Brand Network).
Readers can visit https://www.TinyGems.com, contact Editor@TinyGems.com, or text "Gems" to 888-902-4192 (U.S. Mobile Phones Only) to receive SMS alerts.
The content mentions Calidi Biotherapeutics Inc. (NYSE American: CLDI) as another player in the immune-oncology R&D field, though it notes it remains to be seen what they make of this new discovery.
The discovery was published in Cell Reports Medicine, and readers can access it through the provided link to the journal article.
Curated from InvestorBrandNetwork (IBN)
